Results 121 to 130 of about 6,506,258 (188)

Non‐Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Bispecific antibodies (BsAbs) redirect T‐cells to tumor antigens in an MHC‐independent manner. These universally available, off‐the‐shelf products have demonstrated unprecedented efficacy in heavily pretreated patients with relapsed/refractory (R/R) hematological malignancies (HMs).
Sohaib Irfan   +7 more
wiley   +1 more source

Digital clubbing in a patient with progressive mantle cell lymphoma.

open access: yes, 1999
Digital clubbing with or without hypertrophic osteoarthropathy may occur in a variety of neoplastic diseases. We present the first description of digital clubbing in a patient with progressive mantle cell lymphoma, in the absence of any other apparent ...
Scheiff, Jean-Marie   +5 more
core   +1 more source

Persistent Coronavirus Disease 2019 (COVID‐19) in Patients With Malignant Lymphoma Treated With Anti‐CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases

open access: yesRespirology Case Reports, Volume 14, Issue 11, November 2026.
Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19). We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Switching to an antiviral
Mika Horie   +12 more
wiley   +1 more source

Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase

open access: yesBrazilian Journal of Medical and Biological Research, 2006
We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos   +4 more
doaj  

A Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan

open access: yes
Traditional &Kampo Medicine, Volume 13, Issue 3, December 2026.
Akiko Kikuchi   +4 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

open access: yesCancer Science, Volume 117, Issue 11, Page 3022-3038, November 2026.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao   +8 more
wiley   +1 more source

ANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature

open access: yesNefrología
Kidney involvement in mantle cell lymphoma is rare. We report a case of mantle cell lymphoma diagnosed after rapidly progressive glomerulonephritis with biopsy-proven paraneoplastic anti-neutrophil cytoplasmic antibody positive pauci-immune cresentic ...
Gizem Kumru   +6 more
doaj   +1 more source

Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR‐T Cell Therapy in Oncology: A Systematic Scoping Review

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT CAR‐T therapy has improved outcomes in selected relapsed or refractory hematologic malignancies. However, rational dose‐relevant decision application remains challenging because the administered (nominal) cell dose does not reliably predict in vivo exposure, toxicity, or clinical response.
Dolapo Odujinrin, Graham McClelland
wiley   +1 more source

Therapy-Related Acute Myeloid Leukemia after CAR-T Cell Therapy with Brexucabtagene Autoleucel for Mantle Cell Lymphoma

open access: yesCase Reports in Oncology
Introduction: The introduction of CAR-T cell treatment for relapsed/refractory (r/r) mantle cell lymphoma improved survival rates of these patients.
François Volery   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy